Prognostic factors of T4 gastric cancer patients undergoing potentially curative resection

Naoto Fukuda, Yasuyuki Sugiyama, Joji Wada

Abstract

AIM: To investigate the prognostic factors of T4 gastric cancer patients without distant metastasis who could undergo potentially curative resection.

METHODS: We retrospectively analyzed the clinical data of 71 consecutive patients diagnosed with T4 gastric cancer and who underwent curative gastrectomy at our institutions. The clinicopathological factors that could be associated with overall survival were evaluated. The cumulative survival was determined by the Kaplan-Meier method, and univariate comparisons between the groups were performed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazard model and a step-wise procedure.

RESULTS: The study patients comprised 53 men (74.6%) and 18 women (25.4%) aged 39-89 years (mean, 68.9 years). Nineteen patients (26.8%) had postoperative morbidity: pancreatic fistula developed in 6 patients (8.5%) and was the most frequent complication, followed by anastomosis stricture in 5 patients (7.0%). During the follow-up period, 28 patients (39.4%) died because of gastric cancer recurrence, and 3 (4.2%) died because of another disease or accident. For all patients, the estimated overall survival was 34.1% at 5 years. Univariate analyses identified the following statistically significant prognostic factors in T4 gastric cancer patients who underwent potentially curative resection: peritoneal washing cytology \((P < 0.01)\), number of metastatic lymph nodes \((P < 0.05)\), and venous invasion \((P < 0.05)\). In multivariate analyses, only peritoneal washing cytology was identified as an independent prognostic factor (HR = 3.62, 95% CI = 1.37-9.57) for long-term survival.

CONCLUSION: Positive peritoneal washing cytology was the only independent poor prognostic factor for T4 gastric cancer patients who could be treated with potentially curative resection.
Histological classification and staging were principally based on the seventh edition of the International Union Against Cancer (UICC) TNM classification[9]. We evaluated clinicopathological factors of T4 gastric cancer patients that could be associated with overall survival. These parameters were age, gender, tumor diameter, histological type, lymph node metastasis, metastatic lymph node ratio (MLR), lymphatic invasion (ly), venous invasion (v), and peritoneal washing cytology (CY). For statistical analysis, the patients were grouped into 2 categories with respect to age [≤ 68 years or > 68 years (mean value)], tumor diameter [≤ 84 mm or > 84 mm (mean value)], histological type (differentiated or undifferentiated), number of metastatic lymph nodes (N0 or N1 vs N2 or N3)[9], MLR [≤ 0.27 or > 0.27 (mean value)], and peritoneal washing cytology (CY0 or CY1)[9]. Similarly, the patients were divided into 2 groups with respect to lymphatic invasion (ly0 or ly1 vs ly2 or ly3) and venous invasion (v0 or v1 vs v2 or v3) according to the Japanese Gastric Cancer Association (JGCA) system[9]. Post-operative morbidity and mortality were defined as operation-related complications or death that occurred within 30 days after surgery.

The observation period ended on July 31, 2010. The median follow-up duration from the date of surgery was 24 mo (range, 1-89 mo). Fifty patients (70.5%) were given post-operative adjuvant chemotherapy using S-1 for 29 patients, UFT for 7 patients, paclitaxel for 7 patients, and others for 7 patients. The cumulative survival was determined by the Kaplan-Meier method, and univariate comparisons between the groups were performed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazard model and a step-wise procedure. P value differences less than 0.05 were considered significant.

RESULTS
Sixty-one patients (85.9%) had lymph node metastasis, 9 (12.7%) had N1, 18 (25.4%) had N2, and 34 (47.9%) had N3 disease. Differenitated tumors were histologically revealed in 31 patients and undifferentiated tumors were seen in 40 patients. The degree of lymphatic invasion according to the JGCA system[9] were 0.0%, 23.9%, 45.1%, and 31.0% for ly0, ly1, ly2, and ly3, respectively. The degree of venous invasion according to the JGCA system[9] were 32.4%, 42.3%, 23.9%, and 1.4% for v0, v1, v2, and v3, respectively. Twenty-seven patients (38.0%) were positive for peritoneal washing cytology. Patient characteristics are presented in Table 1. Nineteen patients (26.8%) had postoperative morbidity. Pancreatic fistula occurred in 6 patients (8.5%) and was the most frequent complication, followed by anastomosis stenosis in 5 patients (7.0%). Three patients (4.2%) died of post-operative complications: 2 were due to multi-organ failure associated with pancreatic fistula, and 1 was due to acute gangrenous cholecystitis combined with peritonitis. These complications are listed in Table 2. Thirty-one patients (43.7%) died during the follow-up period. Of these, 28 were related to recurrence of gastric cancer, and 3 were due to another disease or accident. The estimated overall survival at 5 years and the median survival time (MST) for all patients...
were 34.1% (Figure 1) and 19 mo, respectively.

The clinicopathological records of the 71 patients and the 5-year survival rates are shown in Table 3. The statistically significant prognostic factors were peritoneal washing cytology ($P < 0.01$), number of metastatic lymph nodes ($P < 0.05$), and venous invasion ($P < 0.05$). The 5-year overall survival rate of the patients with positive peritoneal washing cytology was 15.2%, which was significantly decreased compared to patients with negative peritoneal washing cytology (47.6%). The 5-year overall survival rate of patients with N2 or N3 was 23.8%, which was significantly poorer than patients with N0 or N1 (67.4%). Similarly, the 5-year overall survival rate of patients with v2 or v3 was 9.7%, which was significantly decreased compared to patients with v0 or v1 (45.7%). The tumor diameter, degree of lymphatic invasion, and histological classification were not significant prognostic factors according to the results of the univariate analysis. In multivariate analysis, only peritoneal washing cytology was identified as an independent prognostic factor (HR = 3.62, 95% CI = 1.37-9.57) for long-term survival (Table 4).

**DISCUSSION**

Owing to the progression of surgical techniques and the
standardization of curative R0 resection, the prognosis of the patients with gastric cancer has been improved in recent years. Nevertheless, patients with advanced gastric carcinoma, especially serosa invading locally advanced tumor diagnosed as T4 in TNM classification[3], still have a poor prognosis[10]. The poor prognosis associated with T4 advanced gastric cancer may result from the presence of incurable factors including distant lymph node involvement, peritoneal metastasis, and hematogenous metastasis such as liver metastasis[11]. If a patient with T4 gastric carcinoma does not have the incurable factors mentioned above, a relatively better survival can be expected when curative surgery regardless of en-block multi-organ resection is achieved. Various T4 gastric carcinoma prognostic factors have been reported in the literature. Kunisaki et al[12] reported that tumor diameter (> 100 mm) and lymph node metastases (more than 7) are poor prognostic factors in T4 gastric cancer patients and concluded that curative surgery with multi-organ resection is indicated for patients with few metastatic lymph nodes (6 or less) and a relatively small tumor diameter (≤ 100 mm). Similarly, several reports suggested that tumor size in gastric cancer is a significant prognostic factor, and large gastric cancers with a diameter > 80 mm have more aggressive behavior and frequent peritoneal recurrences[12,13]. However, our study revealed that the tumor size was not a significant prognostic factor in T4 gastric carcinoma patients who could undergo potentially curative resection. The divergent conclusions of these reports[12,13] with ours might be explained by different patient populations.

Our study was limited to patients with T4 gastric carcinoma without distant metastasis and who were treated with potentially curative resection, whereas other studies[4,12,13] included patients with distant metastasis. Therefore, tumor size may not be a significant prognostic factor in T4 gastric carcinoma, if the patient does not have distant metastasis and can be treated with curative resection.

Lymph node metastasis is a commonly reported prognostic factor for poor outcome in patients with T4 gastric carcinoma[4,11,14]. Saito et al[14] reported that infiltrative type and lymph node metastasis were independent poor prognostic factors in curatively resected patients with T4 gastric carcinoma, and stated that multi-organ resection does not seem to be effective even when curative resection is performed in infiltrating tumors with lymph node metastasis. Jeong et al[15] revealed that lymph node metastasis (greater than pN3) was an independent poor prognostic factor for patients with T4 gastric carcinoma who underwent curative surgery, and concluded that curative resection does not seem to be effective in patients with extensive lymph node metastasis (more than N3). In our study, although patients with more extensive lymph node metastasis (N2 or N3) had a significantly poorer prognosis compared to patients in whom lymph node metastasis was limited (N0 or N1) according to the results of univariate analysis, multivariate analysis revealed that lymph node metastasis was not an independent prognostic factor for T4 gastric cancer patients who underwent potentially curative resection. Although the degree of lymph node metastasis influences surgical outcomes in patients with T4 gastric carcinoma, a relatively good prognosis can be expected with curative R0 resection followed by adjuvant chemotherapy even if the patient has extensive lymph node metastasis (N2 or N3).

In this study, positive peritoneal washing cytology was identified as the only independent prognostic factor for T4 gastric cancer patients who underwent potentially curative resection. Several reports[16-21] have emphasized the prognostic significance of intra-peritoneal free cancer cells for potentially curable serosa-invaded gastric carcinoma. Intra-peritoneal free cancer cells which may be exfoliated mainly from the serosal surface of the stomach penetrated by the primary tumor, are closely related to peritoneal dissemination[10]. Therefore, detection of intra-peritoneal free cancer cells that might have already seeded at the time of operation but cannot be found macroscopically is a key point for influencing the prognosis of T4 gastric cancer patients and for adjuvant treatment planning for those patients. Euanoraset et al[17] reported that all patients with positive peritoneal washing cytology developed peritoneal recurrence, with no patient surviving more than 5 years, and that the sensitivity of peritoneal washing cytology in predicting peritoneal recurrence was only 61% regardless of its high specificity (100%). In addition, the sensitivity of peritoneal washing cytology was previously reported as relatively low, ranging from 14% to 70%[16,22-24]. The relatively high false-negative rate might arise from technical flaws such as incomplete sampling during the lavage process[17]. Recently, the real-time quantitative polymerase chain reaction (PCR) technique has made it possible to detect the presence of only a few cancer cells in the abdominal cavity and this technique is more sensitive than traditional peritoneal lavage cytology[26,27]. Katsuragi et al[18] reported that the prognosis of patients with isolated tumor cells in the peritoneal lavage fluid detected by PCR-based identification was significantly poorer than the prognosis for PCR-negative patients in T4 gastric cancer. Therefore, detection of intra-peritoneal free cancer cells should be the most important and useful way to infer surgical outcome and prognosis of T4 gastric cancer patients. According to the results, T4 gastric cancer patients with positive peritoneal washing cytology might be treated in the same way as for the patients with peritoneal metastasis. More aggressive adjuvant chemotherapy such as S-1 plus cisplatin[15] or DCF[28] should be indicated for patients with T4 gastric cancer with positive peritoneal washing cytology that could undergo potentially curative resection to improve prognosis.

**COMMENTS**

**Background**

Although the incidence of gastric cancer has declined particularly in Western countries, the disease remains the fourth most common cancer and continues to be the second leading cause of cancer death worldwide. The therapeutic strategy for advanced gastric carcinoma, such as T4 locally advanced gastric carcinoma, is to improve the prognosis of all gastric cancer patients, since surgical results for early stage gastric carcinoma are satisfactory.

**Innovations and breakthroughs**

In this study, patients included were limited to T4 advanced gastric carcinoma without distant metastasis who could be treated with potentially curative resec-
This is an interesting work that underlines the prognostic value of peritoneal cytology in curatively resected T4 gastric carcinomas. The text is well-organized and the key points are clearly described.

REFERENCES

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.

2. Levi F, Lucchini F, Gonzalez JR, Negri E, La Vecchia C. Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 2004; 15: 338-345.

3. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228: 449-461.

4. Kunisaki C, Akiyama H, Nomura M, Matsuuda G, Otsuka Y, Ono HA, Nagahori Y, Takahashi M, Kito F, Shimada H. Surgical outcomes in patients with T4 gastric cancer. J Am Coll Surg 2006; 202: 223-230.

5. Sobin LH, Gospodarowicz MK, Wittekind Ch, editors. International union against cancer TNM classification of malignant tumors. 7th ed. New Jersey: Wiley-Blackwell, 2009.

6. Schepotin IB, Chorny VA, Nauta RJ, Shabahang M, Buras R, Evans SR. Extended surgical resection in T4 gastric cancer. Am J Surg 1998; 175: 123-6.

7. ISOZAKI H, Tanaka N, Tanigawa N, Okajima K. Prognostic factors in patients with advanced gastric cancer with macroscopic invasion to adjacent organs treated with radical surgery. Gastric Cancer 2000; 3: 202-210.

8. Neugut AI. Epidemiology of gastric cancer. Semin Oncol 1996; 23: 281-291.

9. Japanese Gastric Cancer Association. Japanese Classification of Gastric Cancer - 2nd English Edition. Gastric Cancer 1998; 1: 10-24.

10. Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg 2002; 235: 159-165.

11. Jeong O, Choi WY, Park YK. Appropriate selection of patients for combined organ resection in cases of gastric carcinoma involving adjacent organs. J Surg Oncol 2009; 100: 115-120.

12. Kobayashi O, Tsunahara A, Yoshikawa T, Otsuji T, Murakami H, Yoshida T, Saireny M. The efficacy of gastrectomy for large gastric cancer. Int J Clin Oncol 2006; 11: 44-50.

13. Shiraiishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol 2007; 96: 14-18.

14. Saito H, Tsujitani S, Maeda Y, Fukuda K, Yamaguchi K, Ikeguchi M, Maeta M, Kaibara N. Combined resection of invaded organs in patients with T4 gastric carcinoma. Gastric Cancer 2001; 4: 206-211.

15. Boku T, Nakane Y, Minoura T, Takada H, Yamamura M, Hikoi K, Yamamoto M. Prognostic significance of serial invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg 1990; 77: 436-439.

16. Wu CC, Chen JT, Chang MC, Ho WL, Chen CY, Yeh DC, Liu TJ, Feng PK. Optimal surgical strategy for potentially curable serosa-involved gastric carcinoma with intraperitoneal free cancer cells. J Am Coll Surg 1999; 184: 611-617.

17. Shiraishi N, Yasui K, Morimoto T, Kato T, Kito H, Fujishita S, Fujimura T, Yamamura Y, Shimizu Y, Torii A, Ohta T, Cai Y, Ruan J, Li J, Wu CC, Chen JT, Chang MC, Ho WL, Chen CY, Yeh DC, Liu TJ, Feng PK. Optimal surgical strategy for potentially curable serosa-involved gastric carcinoma with intraperitoneal free cancer cells. J Am Coll Surg 1999; 184: 611-617.

18. Torre LA, Ferlay J, Rosenberg R, Ferlay J, Parkin DM. Prognostic significance of peritoneal washing cytology in patients with gastric adenocarcinoma undergoing curative D2 gastrectomy. Gastric Cancer 2007; 10: 18-23.

19. Katsuragi K, Yoshino S, Sawada T, Osaka H, Ohira M, Hirokawa K. Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer 2007; 97: 550-556.

20. Homma Y, Ushida S, Yamada M, Kobayashi H, Suzuki K. Positive peritoneal washing cytology in multiple cavities can predict poor prognosis of advanced gastric cancer patients. Ann Surg Oncol 2010; 17: 363-365.

21. Martin RC, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fujiyama A, Fujimura T, Nishimura T, Miwa K, Inoue K, Ikeda N, Ichinose K, Nakamura Y, Shimada H, Isozaki K, Ohashi T, Hayashi H, Hori S, Shimada H, Isozaki K. Peritoneal lavage cytology findings as prognostic factor for gastric cancer. Semin Surg Oncol 1999; 17: 103-107.

22. Kodera Y, Nakamichi H, Yamamura Y, Shimizu Y, Torii A, Hiraizumi T, Yasui K, Morimoto T, Kato T, Kito H, Tatsumi T. Prognostic value and therapeutic consequences of peritoneal washout in gastric cancer patients. Eur J Surg Oncol 2004; 30: 982-986.

23. Cetin B, Atalay C, Akin S, Babacan B, Hatipoglu C, Akinci M, Cetin A. Peritoneal carcinomembrane antigen level for predicting locoregional and distant spread of gastric cancer. Surg Today 2005; 35: 919-924.

24. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fujiyama A, Fujimura T, Nishimura T, Miwa K, Inoue K, Ikeda N, Ichinose K, Nakamura Y, Shimada H, Isozaki K, Ohashi T, Hayashi H, Hori S, Shimada H, Isozaki K. Peritoneal lavage cytology findings as prognostic factor for gastric cancer. Semin Surg Oncol 1999; 17: 103-107.

25. Kodera Y, Nakamichi H, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T, Kito H, Tatsumi T. Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer 1998; 79: 429-433.

26. Timar J, Csoka O, Orosz Z, Jeney A, Kopper L. Molecular pathology of tumor metastasis. II. Molecular staging and differential diagnosis. Pathol Oncol Res 2002; 8: 204-219.

27. Koizumi W, Naraohara H, Hara T, TakaAnezane A, Akiyama T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toy Y, Nagaie T, Takagi S, Yamamura Y, Yano A, Orita H, Takeuchi M, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.

28. Ajani JA, Moiseenko VM, Tulandiin S, Majlis A, Conslenina M, Boni C, Rodrigues A, Fodor M, Chao Y, Vezney I, Marabottini C, Van Cutsem E. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25: 3205-3209.